Levetiracetam-mediated emotional behavior in heterozygous rolling Nagoya CaV2.1 channel mutant mice

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 3, 2010, Pages 294-300

  Takahashi, Eiki ^a   Niimi, Kimie ^a   Itakura, Chitoshi ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Cav2.1 1 mutation; Emotional behavior; Levetiracetam; Phosphorylated tryptophan hydroxylase at serine 58; Rolling mouse Nagoya; Serotonin

Indexed keywords

ETIRACETAM; SERINE; SEROTONIN; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL 2.1; ANTICONVULSIVE AGENT; CALCIUM CHANNEL N TYPE; DOPAMINE; PIRACETAM; VOLTAGE-DEPENDENT CALCIUM CHANNEL (P-Q TYPE);

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; BRAIN STEM; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; EMOTION; FORCED SWIMMING TEST; HETEROZYGOSITY; LIGHT DARK CYCLE; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; GENOTYPE; IMMOBILIZATION; METABOLISM; MUTATION; PHYSIOLOGY; PSYCHOLOGY; SWIMMING; SYNAPSE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTICONVULSANTS; ANXIETY; BLOTTING, WESTERN; BRAIN STEM; CALCIUM CHANNELS, N-TYPE; DOPAMINE; EMOTIONS; EXPLORATORY BEHAVIOR; GENOTYPE; HINDLIMB SUSPENSION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PIRACETAM; SEROTONIN; SWIMMING; SYNAPSES; TRYPTOPHAN HYDROXYLASE;

MUS;

EID: 77954819590     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.020     Document Type: Article

References (39)

1. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000, 1:11-21.
2. 2+ channels and their role in neurotransmitter release. Cell Calcium 1998, 24:307-323.
3. 2+ channels and snare proteins in neurotransmitter release. Ann NY Acad Sci 1999, 868:144-159.
4. Crawley J.N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 1981, 15:695-699.
5. Crawley J.N. Animal models for anxiety. Curr Sci 1989, 2:773-776.
6. Fletcher C.F., Lutz C.M., O'Sullivan T.N., J.D.Shaughnessy, Hawkes R., Frankel W.N., et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996, 87:607-617.
7. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
8. Gower A.J., Falter U., Lamberty Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol 2003, 481:67-74.
9. Harvey J., Wedley S., Findlay J.D., Sidell M.R., Pullar I.A. Omega-Agatoxin IVA identifies a single calcium channel subtype which contributes to the potassium-induced release of acetylcholine, 5-hydroxytryptamine, dopamine, gamma-aminobutyric acid and glutamate from rat brain slices. Neuropharmacology 1996, 35:385-392.
10. Husum H., Bolwig T.G., Sánchez C., Mathé A.A., Hansen S.L. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 2004, 5:204-215.
11. Janz R., Goda Y., Geppert M., Missler M., Sudhof T.C. SV2A and SV2B function as redundant calcium regulators in neurotransmitter release. Neuron 1999, 24:1003-1016.
12. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
13. +-evoked serotonin release. Br J Pharmacol 2001, 133:557-567.
14. Klitgaard H., Pitkänen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003, 5(Suppl 1):S9-S16.
15. Kuhn D.M., Arthur R., JCJr States Phosphorylation and activation of brain tryptophan hydroxylase: identification of serine-58 as a substrate site for protein kinase. J Neurochem 1997, 68:2220-2223.
16. Lamberty Y., Falter U., Gower A.J., Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. Eur J Pharmacol 2003, 469:97-102.
17. Lee C.Y., Chen C.C., Liou H.H. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 2009, 158:1753-1762.
18. Liu L., Zwingman T.A., Fletcher C.F. In vivo analysis of voltage-dependent calcium channels. J Bioenerg Biomembr 2003, 35:671-865.
19. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
20. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic druglevetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
21. Mazza M., Martini A., Scoppetta M., Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiat 2008, 32:539-543.
22. 2+ channel subtype of chromaffin cells. J Neurochem 2003, 86:1477-1486.
23. Mikami A., Imoto K., Tanabe T., Niidome T., Mori Y., Takeshima H., et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 1989, 340:230-233.
24. Mori Y., Wakamori M., Oda S., Fletcher C.F., Sekiguchi N., Mori E., et al. Reduced voltage sensitivity of activation of P/Q-type Ca2+ channels is associated with the ataxic mouse mutation rolling Nagoya (tg(rol)). J Neurosci 2000, 20:5654-5662.
25. Oda S. The observation of rolling mouse Nagoya (rol), a new neurological mutant, and its maintenance. Exp Anim 1973, 22:281-286.
26. Papp L.A. Safety and efficacy of levetiracetam for patients with panic disorders: results of an open-label fixed-flexible dose study. J Clin Psychiatry 2006, 67:1573-1576.
27. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 1985, 14:149-167.
28. Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F., et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45:719-728.
29. Porsolt R.D., Bertin A., Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978, 51:291-294.
30. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002, 136:659-672.
31. 2 receptor ligands modulate the behaviour of mice in the elevated plus maze. Pharmacol Biochem Behav 1994, 49:985-995.
32. Simon N.M., Worthington J.J., Doyle A.C., Hoge E.A., Kinrys G., Fischman D., et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004, 65:1219-1222.
33. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
34. Takahashi E., Niimi K., Itakura C. Emotional behavior in heterozygous rolling mouse Nagoya Cav2.1 channel mutant mice. Neurobiol Aging 2009, 10.1016/j.neurobiolaging.2009.03.001.
35. Takahashi E., Niimi K., Itakura C. Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice. Brain Res 2009, 1279:50-57.
36. Yokoyama C.T., Myers S.J., Fu J., Mockus S.M., Scheuer T., Catterall W.A. Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site. Mol Cell Neurosci 2005, 28:1-17.
37. Zhang W., Connor K.M., Davidson J.R.T. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 2005, 19:551-553.
38. Zhou Q.Y., Palmiter R.D. Dopamine-deficient mice are severely hypoactive, adiposic, and aphagic. Cell 1995, 83:1197-1209.
39. Zhuang X., Gross C., Santarelli L., Compan V., Trillat A.C., Hen R. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 1999, 21(suppl 2):S52-S60.